Weiss Valuation: Where Does ABT Stand Today?
At 2.88%, ABT's current yield is near the top of its 10-year historical range (1.48%–2.20%), reaching 131% of its historical maximum. This places the stock firmly in historically undervalued territory by the Weiss method — the kind of entry point that has preceded strong long-term returns for income investors.
The undervalued price threshold — the level at which ABT historically becomes an attractive buy — currently sits at $110.69. The overvalued threshold, above which the stock is historically expensive, is $165.13. The current price of $84.74 places the stock below the undervalued band — a historically rare buying opportunity.
Dividend Quality Assessment
Abbott Laboratories scores 69/100 on DividendVisual's quality scale — a Good rating, indicating a well-covered, growing dividend with manageable risk. Key metrics: a 67% payout ratio, the dividend consumes 69% of free cash flow, growing at 10.4% annually over the past 5 years.
Abbott Laboratories has maintained its dividend without a cut for 9 years, establishing a meaningful income track record.
The current payout ratio is 67% — a moderate level. The dividend is well-covered but investors should monitor any trend toward higher payout.
10-Year Yield History
Over the past decade, Abbott Laboratories's dividend yield has ranged from a low of 1.48% (when the stock was most expensive relative to its dividend) to a high of 2.20% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 1.83%.
Investors who consistently bought ABT near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.
Income Projection: What ABT Could Generate
A $10,000 investment at the current price and yield would generate approximately $288 in year-one income. With dividends reinvested and a 10.4% annual growth rate maintained, that same investment would produce roughly $1,278 per year in income by year 10 — a yield on cost of 12.8%.
These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.
Key Risks to Consider
Abbott Laboratories's dividend appears well-supported by current earnings and cash flow. No material red flags are flagged by the quality model, though macro risks (rising rates, sector disruption) always apply.
Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. Abbott Laboratories's position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.
Bottom Line
Abbott Laboratories currently offers a historically attractive entry point for income investors. The combination of an above-median yield, a quality score of 69/100, and 9 years of dividend growth makes a compelling case for consideration at current levels. As always, position sizing and portfolio context matter — but the Weiss signal here is meaningful.